Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (LTRN) announced that its RADR® AI platform has surpassed 4.6 billion datapoints, marking a 16-fold increase over the past year. This advancement enhances the platform's drug discovery capabilities across various cancers, focusing on personalized oncology therapeutics. CEO Panna Sharma highlighted the importance of this milestone in speeding up drug development and increasing collaboration opportunities in the biopharma sector. Additionally, Lantern filed two new patents to protect its innovations in AI-driven drug development.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2021, at 4:30 p.m. ET to discuss its first-quarter financial and operating results for the period ending March 31, 2021. The call will feature CEO Panna Sharma and other management members. Lantern Pharma utilizes its proprietary RADR® A.I. platform to advance oncology therapeutics and identify responsive patients. More details on the call can be accessed via the company’s website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced the publication of a manuscript in Oncotarget detailing the efficacy of its drug candidate, LP-184, for treating non-small cell lung cancer (NSCLC). LP-184 has shown nanomolar potency against therapy-resistant NSCLC models, surpassing conventional chemotherapeutics in effectiveness. The unmet need addresses patients resistant to current therapies, with 30-40% of lung cancers lacking targetable mutations. The research identifies patient subgroups likely to respond to LP-184, supporting its potential as a viable treatment option in oncology.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the virtual 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Panna Sharma will engage in a fireside chat on April 15 at 12:45 pm ET and conduct one-on-one investor meetings during the event. The session will be livestreamed and accessible for 90 days on their investor relations website. Lantern Pharma is advancing its proprietary RADR® A.I. platform for oncology drug development, focusing on genomic-targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical firm, announced a collaboration with Johns Hopkins Pediatric Oncology for its drug candidate LP-184, targeting Atypical Teratoid Rhabdoid Tumors (ATRT) in children, an aggressive brain cancer with no effective treatments. The partnership aims to explore LP-184's efficacy across multiple central nervous system cancers, leveraging Lantern's RADR® AI platform. The FDA's Rare Pediatric Disease Designation may enhance LP-184's development, potentially qualifying for a Priority Review Voucher, adding significant value for Lantern's future prospects.
Lantern Pharma (NASDAQ: LTRN) announced it will present new findings on LP-184, a targeted small molecule for prostate cancer, at the AACR Virtual Annual Meeting from April 10-15, 2021. The data highlights LP-184's effectiveness against DNA damage repair defects found in 25-30% of metastatic prostate cancer patients. CEO Panna Sharma noted the potential for LP-184 to exhibit best-in-class efficacy, particularly in tumors with specific genetic mutations. The findings will be showcased in a poster presentation during the conference.
Lantern Pharma (NASDAQ: LTRN) announced the filing of seven global patent applications for a new DNA-damaging agent, LP-284, with demonstrated anticancer properties. LP-284, a preclinical small molecule candidate, shows promise in various cancer indications by inhibiting DNA damage and repair mechanisms. The distinct characteristics of LP-284, as a stereoisomer of LP-184, may enhance its therapeutic potential and integration into Lantern's portfolio. This strategic move reflects Lantern's ongoing commitment to advancing targeted oncology therapies through its RADR® A.I. platform.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced that CEO Panna Sharma will be featured in an interview on The RedChip Money Report on Bloomberg TV on March 13, 2021, at 7 p.m. local time. The discussion will cover the company's development pipeline, including its new Antibody Drug Conjugate program and collaborations with cancer centers. Lantern is advancing its genomically-targeted cancer therapeutics through its proprietary RADR® A.I. platform, aiming to improve patient outcomes.
Lantern Pharma (NASDAQ: LTRN) announced its fourth quarter and fiscal year 2020 results, highlighting key operational achievements and financial metrics. The company completed a public offering raising $69.0 million in January 2021, strengthening its balance sheet. Lantern's cash and equivalents stood at $19.2 million at year-end. R&D and G&A expenses increased significantly due to expansions in research activities and public company expenses. Notably, net losses were $2.9 million for Q4 2020, up from $0.7 million in Q4 2019. The company anticipates a transformational 2021 with advancements in drug trials and collaborations.
Lantern Pharma (NASDAQ: LTRN) will host a conference call on March 10, 2021, at 4:00 p.m. ET to discuss its fourth quarter and fiscal year 2020 results. The conference will be led by Panna Sharma, CEO, along with the management team. Participants can join via phone or online at their official webcast link. A replay will be available until April 10, 2021. Lantern Pharma utilizes its RADR® A.I. platform for drug discovery and aims to enhance patient outcomes through precision therapeutics, focusing on unmet clinical needs in oncology.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
